News | October 31, 2025
BMS’ Cobenfy sees steady start, eyes stronger growth ahead
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
Label updates reflect growing body of real-world evidence and regulatory confidence in the safety profile of the class of CD19- and BCMA-directed autologous CAR T cell therapies, reinforcing efforts to increase equitable access
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Subscribe To Our Newsletter & Stay Updated
